PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Hold” by Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCT) has received an average rating of “Hold” from the sixteen ratings firms that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $37.64.

Several brokerages recently commented on PTCT. Robert W. Baird began coverage on PTC Therapeutics in a research report on Wednesday, September 4th. They set an “outperform” rating and a $44.00 price target for the company. Barclays increased their price objective on PTC Therapeutics from $25.00 to $31.00 and gave the company an “equal weight” rating in a report on Friday, August 9th. Baird R W raised shares of PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Bank of America lifted their price objective on shares of PTC Therapeutics from $25.00 to $32.00 and gave the company an “underperform” rating in a research report on Friday, June 21st. Finally, UBS Group began coverage on shares of PTC Therapeutics in a report on Monday, August 26th. They issued a “buy” rating and a $47.00 target price on the stock.

Insider Activity

In related news, CFO Pierre Gravier sold 2,269 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $34.02, for a total value of $77,191.38. Following the completion of the sale, the chief financial officer now directly owns 53,531 shares in the company, valued at approximately $1,821,124.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.50% of the stock is owned by company insiders.

Institutional Trading of PTC Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC acquired a new position in PTC Therapeutics in the 1st quarter valued at $46,000. Quest Partners LLC bought a new stake in shares of PTC Therapeutics during the 2nd quarter worth approximately $128,000. Quarry LP boosted its position in shares of PTC Therapeutics by 100.0% during the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 2,500 shares in the last quarter. Lazard Asset Management LLC increased its stake in PTC Therapeutics by 268.9% in the first quarter. Lazard Asset Management LLC now owns 6,504 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 4,741 shares during the last quarter. Finally, Headlands Technologies LLC raised its position in PTC Therapeutics by 83.2% during the second quarter. Headlands Technologies LLC now owns 6,611 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 3,002 shares in the last quarter.

PTC Therapeutics Stock Performance

NASDAQ:PTCT opened at $37.66 on Friday. The company has a market cap of $2.89 billion, a PE ratio of -4.90 and a beta of 0.64. The stock has a 50-day simple moving average of $33.68 and a 200 day simple moving average of $32.58. PTC Therapeutics has a 52-week low of $17.53 and a 52-week high of $40.69.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.16). The business had revenue of $186.70 million for the quarter, compared to analysts’ expectations of $192.12 million. On average, research analysts predict that PTC Therapeutics will post -5.09 earnings per share for the current fiscal year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.